The size of the Asia Pacific Generic drugs market is forecasted to grow USD 122.28 billion by 2026 from USD 81.93 billion in 2021, registering a CAGR of 8.34% from 2021 to 2026.
Generic drugs are flourishing in the healthcare sector. An increase in the demand for generic drugs over branded drugs because they are cost-efficient, is the major driver in the generic drugs market in the APAC region. In addition, the generic drugs are of the same quality, have the same ingredients as the branded drugs, and are also FDA (Food and Drug Administration) approved.
The need for medication is driven by the rising elderly population and the burden of acute and chronic illnesses. As people in these countries still cannot afford high-rated medicines, therefore, they choose generic medicines.
High marketing of branded drugs overshadows generics is expected to hamper the growth rate of the APAC generic drugs market. Under certain conditions, physicians prefer branded drugs over generic drugs. It includes brands influencing the physicians, brand loyalty towards the brand medicines. Therefore, the branded medicines are overshadowing generic drugs. And also due to the rapid increase in the competition in the healthcare sector.
Impact of COVID-19 on the APAC generic drugs market:
COVID-19 has had a direct influence on supply and demand, as well as causing supply chain disruption since several medications were unable to reach the market on time. In addition, many clinical experiments were halted due to the pandemic, and pharma manufacturing businesses also suffered losses due to supply and demand issues. The COVID-19 epidemic impacted the APAC generic medicine market because hospitals, healthcare facilities, and medication manufacturers were severely decreased due to social distancing measures adopted by governments throughout the world.
This research report on the Asia-Pacific generic drugs market has been segmented and sub-segmented into the following categories:
During the forecast period, the Indian generic drugs market is estimated to lead the APAC market and had accounted for a substantial share in 2020. India is the world's top supplier of generic medicines. For example, the Indian pharmaceutical industry supplies more than half of the worldwide demand for vaccines, 40% of generic demand in the United States, and 25% of all medication in the United Kingdom. India is the world's largest producer of pharmaceuticals by volume and the fourteenth-largest producer by value. India is dominated by generic medicines in the pharmaceutical business, which account for 71% of the market share. In 2021, India's domestic pharmaceutical industry is expected to be worth US$ 42 billion, rising to US$ 65 billion by 2024 and US$ 120-130 billion by 2030.
The Chinese generic drugs market is anticipated to register a healthy CAGR during the forecast period. In the generic drug market, the sales value of Atorvastatin in the Chinese market is expected to accelerate from 2021 to 2025 due to the effective alleviation of COVID-19.
The Japanese generic drugs market is another lucrative regional market in Asia-Pacific. In terms of value, Japan is one of the world's largest markets for generic medicines and is expected to grow significantly during the forecast period. Japan has a large aging population, which results in high medical expenses; by recognizing the country's aging population as well as the rising prices of branded medications, the Japanese government began implementing healthcare policy measures to reduce medical spending, which is estimated to be creating great opportunities for both the manufactures.
KEY MARKET PLAYERS:
A few of the noteworthy companies operating in the Asia-Pacific generic drugs market profiled in the report are Ranbaxy Laboratories, Ltd, Actavis, Mylan, Inc., Industries, Ltd., Dr. Reddy’s Laboratories, Par Pharmaceutical, Inc., Sandoz International GmbH, Hospira, Inc., Apotex, Inc., Watson Pharmaceuticals, Ltd., Teva Pharmaceutical and others.
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1.3 simple generics
5.1.4 Super generics
5.1.5 Y-o-Y Growth Analysis, By Product
5.1.6 Market Attractiveness Analysis, By Product
5.1.7 Market Share Analysis, By Product
5.2 Therapeutic drugs
5.2.2 Cardiovascular Products
5.2.3 Anti-infective Drugs
5.2.4 Anti Arthritis Drugs
5.2.5 Central Nervous System Drugs
5.2.6 Anti Cancer Drugs
5.2.7 Respiratory System Drugs
5.2.9 Y-o-Y Growth Analysis, By Therapeutic Drugs
5.2.10 Market Attractiveness Analysis, By Therapeutic Drugs
5.2.11 Market Share Analysis, By Therapeutic Drugs
6. Geographical Analysis
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
126.96.36.199 By Geographical Area
188.8.131.52 By Type
184.108.40.206 By Therapeutic Drugs
6.1.4 Market Attractiveness Analysis
220.127.116.11 By Geographical Area
18.104.22.168 By Type
22.214.171.124 By Therapeutic Drugs
6.1.5 Market Share Analysis
126.96.36.199 By Geographical Area
188.8.131.52 By type
184.108.40.206 By Therapeutic Drugs
6.6 South Korea
7.1 PESTLE analysis
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Ranbaxy Laboratories
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.3 Mylan, Inc. Industries, Ltd.
8.4 Dr. Reddy’s Laboratories
8.5 Par Pharmaceutical, Inc.
8.6 Sandoz International GmbH
8.7 Celgene Corporation
8.8 Apotex, Inc.
8.9 Watson Pharmaceuticals, Ltd.
8.10 Teva Pharmaceutical and others.
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
a) List of Tables
b) List of Figures